Xeris Pharmaceuticals Inc(XERS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

XERS Xeris Pharmaceuticals Inc

Post-Mkt 09-01 17:15:41 EDT

8.43

-0.01

-0.12%

盘后8.43

+0.00+0.01%

16:26 EDT

High8.62	Low8.38	Vol1.14M
Open8.42	D1 Closing8.44	Amplitude2.78%
Mkt Cap1.54B	Tradable Cap1.45B	Total Shares182.32M
T/O9.69M	T/O Rate0.66%	Tradable Shares172.57M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"XERS","market":"US","secType":"STK","nameCN":"Xeris Pharmaceuticals Inc","latestPrice":8.43,"timestamp":1788292800000,"preClose":8.44,"halted":0,"volume":1144081,"hourTrading":{"tag":"盘后","latestPrice":8.431,"preClose":8.43,"latestTime":"16:26 EDT","volume":20834,"amount":175630.661668,"timestamp":1788294403683,"change":0.001,"changeRate":0.000119,"amplitude":0.000119},"delay":0,"changeRate":-0.0011848341232227235,"floatShares":172573639,"shares":182320306,"eps":-0.102003,"marketStatus":"Post-Mkt","change":-0.01,"latestTime":"09-01 17:15:41 EDT","open":8.42,"high":8.615,"low":8.38,"amount":9693005,"amplitude":0.027844,"askPrice":8.5,"askSize":400,"bidPrice":8.43,"bidSize":1,"shortable":3,"etf":0,"ttmEps":-0.102003,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1788307200000},"marketStatusCode":4,"adr":0,"adrRate":0,"listingDate":1529553600000,"exchange":"NASDAQ","adjPreClose":8.44,"preHourTrading":{"tag":"盘前","latestPrice":8.44,"preClose":8.44,"latestTime":"08:18 EDT","volume":3907,"amount":32975.079999999994,"timestamp":1788265131584,"change":0,"changeRate":0,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":8.431,"preClose":8.43,"latestTime":"16:26 EDT","volume":20834,"amount":175630.661668,"timestamp":1788294403683,"change":0.001,"changeRate":0.000119,"amplitude":0.000119},"volumeRatio":0.920661,"impliedVol":0.7984,"impliedVolPercentile":0.4524},"requestUrl":"/m/hq/s/XERS/wiki","defaultTab":"wiki","newsList":[{"id":"2662715985","title":"Xeris to Host XP-8121 Hypothyroidism Program Overview Webinar","url":"https://stock-news.laohu8.com/highlight/detail?id=2662715985","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662715985?lang=en_us&edition=fundamental","pubTime":"2026-08-26 19:31","pubTimestamp":1787743862,"startTime":"0","endTime":"0","summary":"Xeris to host XP-8121 hypothyroidism program overview webinarXeris Biopharma schedules an XP-8121 program overview webinar for September 9, 2026 at 10 a.m. ET.Session focuses on its Phase 3-ready, onc","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260826:nNDLb74PrK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","XERS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660005464","title":"Xeris Biopharma price target raised to $12 from $9 at Barclays","url":"https://stock-news.laohu8.com/highlight/detail?id=2660005464","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660005464?lang=en_us&edition=fundamental","pubTime":"2026-08-20 17:10","pubTimestamp":1787217017,"startTime":"0","endTime":"0","summary":"Barclays raised the firm’s price target on Xeris Biopharma (XERS) to $12 from $9 and keeps an Overweight rating on the shares after meeting with ma...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/xeris-biopharma-price-target-raised-to-12-from-9-at-barclays-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/xeris-biopharma-price-target-raised-to-12-from-9-at-barclays-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","XERS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660490551","title":"Why Xeris Biopharma (XERS) Is Up 6.6% After Tighter 2026 Revenue Guidance And Wider Losses","url":"https://stock-news.laohu8.com/highlight/detail?id=2660490551","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660490551?lang=en_us&edition=fundamental","pubTime":"2026-08-19 04:29","pubTimestamp":1787084970,"startTime":"0","endTime":"0","summary":"Xeris Biopharma Holdings, Inc. reported past second-quarter 2026 results with revenue rising to US$92.1 million from US$71.54 million a year earlier, while net loss widened to US$31.1 million from US$1.93 million and basic loss per share from continuing operations increased to US$0.18 from US$0.01.\nDespite higher losses, the company also reported first-half 2026 revenue of US$175.23 million versus US$131.66 million and tightened its full-year 2026 total revenue guidance to US$385...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-xers/xeris-biopharma-holdings/news/why-xeris-biopharma-xers-is-up-66-after-tighter-2026-revenue","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-xers/xeris-biopharma-holdings/news/why-xeris-biopharma-xers-is-up-66-after-tighter-2026-revenue","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["XERS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659002169","title":"Mission Produce And Two Other Stocks Estimated To Be Trading Below Intrinsic Value","url":"https://stock-news.laohu8.com/highlight/detail?id=2659002169","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659002169?lang=en_us&edition=fundamental","pubTime":"2026-08-14 01:07","pubTimestamp":1786640879,"startTime":"0","endTime":"0","summary":"Over the last 7 days, the United States market has risen by 1.0%, contributing to an impressive 18% climb over the past year, with earnings forecasted to grow by 17% annually. In this context of robust market performance, identifying stocks that are trading below their intrinsic value can offer investors opportunities for potential appreciation while aligning with current growth trends.","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-xers/xeris-biopharma-holdings/news/mission-produce-and-two-other-stocks-estimated-to-be-trading","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-xers/xeris-biopharma-holdings/news/mission-produce-and-two-other-stocks-estimated-to-be-trading","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["GROY","BK4212","AVO","BK4017","BK4007","XERS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659188948","title":"Xeris Biopharma CFO Steven Pieper Sells 5,000 Shares Worth $42,500","url":"https://stock-news.laohu8.com/highlight/detail?id=2659188948","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659188948?lang=en_us&edition=fundamental","pubTime":"2026-08-13 04:45","pubTimestamp":1786567527,"startTime":"0","endTime":"0","summary":"Xeris Biopharma CFO Steven Pieper sells 5,000 shares worth $42,500Xeris Biopharma CFO Steven Pieper sold 5,000 common shares on Aug. 12, 2026 at USD 8.5.Direct holdings fell to 1,361,053 shares.Sale e","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260812:nNDL9jFDKJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Xeris Biopharma CFO Steven Pieper Sells 5,000 Shares Worth $42,500","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","XERS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657632105","title":"Xeris Biopharma Holdings, Inc. Reports Results for the Quarter Ended June 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2657632105","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657632105?lang=en_us&edition=fundamental","pubTime":"2026-08-06 21:31","pubTimestamp":1786023113,"startTime":"0","endTime":"0","summary":"Xeris Biopharma Holdings, Inc. reports results for the quarter ended June 30 - Earnings SummaryXeris Biopharma Holdings, Inc.XERS.OQreported a quarterly adjusted loss of 18 cents per share for the qua","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nL8N4431V8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XERS","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657963214","title":"UPDATE: Xeris Biopharma Holdings Q2 Adj. EPS $0.00, Inline","url":"https://stock-news.laohu8.com/highlight/detail?id=2657963214","media":"Benzinga Earnings","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657963214?lang=en_us&edition=fundamental","pubTime":"2026-08-06 21:31","pubTimestamp":1786023104,"startTime":"0","endTime":"0","summary":"UPDATE: Xeris Biopharma Holdings Q2 Adj. EPS $0.00, Inline","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/quote/XERS","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","XERS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657355686","title":"Earnings Flash (XERS) Xeris Biopharma Posts Q2 Loss $0.18 a Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2657355686","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657355686?lang=en_us&edition=fundamental","pubTime":"2026-08-06 19:34","pubTimestamp":1786016058,"startTime":"0","endTime":"0","summary":"Earnings Flash (XERS) Xeris Biopharma Posts Q2 Loss $0.18 a Share","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["XERS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657742638","title":"Xeris Q2 FY26 Net Loss Widens to $31.1 Million; Revenue Rises 29% to $92.1 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2657742638","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657742638?lang=en_us&edition=fundamental","pubTime":"2026-08-06 19:14","pubTimestamp":1786014878,"startTime":"0","endTime":"0","summary":"Xeris Q2 FY26 net loss widens to $31.1 million; revenue rises 29% to $92.1 millionXeris Biopharma Q2 2026 revenue rose 29% year over year to $92.1 million; net product revenue climbed 34% to $91 milli","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nNDL9Yjbbf:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","XERS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657638401","title":"Xeris Biopharma Holdings Q2 EPS $(0.18) Misses $0.00 Estimate, Sales $92.100M Beat $90.225M Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2657638401","media":"Benzinga Earnings","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657638401?lang=en_us&edition=fundamental","pubTime":"2026-08-06 19:11","pubTimestamp":1786014674,"startTime":"0","endTime":"0","summary":"Xeris Biopharma Holdings (NASDAQ:XERS) reported quarterly losses of $(0.18) per share which missed the analyst consensus estimate of $0.00 by Infinity percent. This is a 1700 percent decrease over losses of $(0.01) per","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/08/60988213/xeris-biopharma-holdings-q2-eps-0-18-misses-0-00-estimate-sales-92-100m-beat-90-225m-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XERS","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657680096","title":"Xeris Biopharma Q2 Net Income USD -31.101 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2657680096","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657680096?lang=en_us&edition=fundamental","pubTime":"2026-08-06 19:01","pubTimestamp":1786014061,"startTime":"0","endTime":"0","summary":"BRIEF-Xeris Biopharma Q2 Net Income USD -31.101 MillionAug 06 (Reuters) - Xeris Biopharma Q2 operating income USD 5.173 million.Q2 product revenue USD 91.004 million vs. IBES estimate USD 90.2 million","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nPLXKDZ29Z:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","XERS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657680736","title":"Xeris Biopharma Q2 EPS USD -0.18","url":"https://stock-news.laohu8.com/highlight/detail?id=2657680736","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657680736?lang=en_us&edition=fundamental","pubTime":"2026-08-06 19:00","pubTimestamp":1786014002,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nPLXKDZ29Z:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","XERS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657063384","title":"Xeris Biopharma Outlook Full-Year 2026 Total Revenue Guidance to $385 Million to $390 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2657063384","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657063384?lang=en_us&edition=fundamental","pubTime":"2026-08-06 19:00","pubTimestamp":1786014002,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nPLXKDZ29Z:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","XERS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657791560","title":"Xeris Biopharma President, COO Kevin McCulloch Sells 15,000 Shares for $120,240","url":"https://stock-news.laohu8.com/highlight/detail?id=2657791560","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657791560?lang=en_us&edition=fundamental","pubTime":"2026-08-05 06:07","pubTimestamp":1785881250,"startTime":"0","endTime":"0","summary":"Xeris Biopharma President, COO Kevin McCulloch sells 15,000 shares for $120,240Xeris Biopharma President, Chief Operating Officer Kevin McCulloch sold 15,000 common shares on Aug. 3, 2026 at USD 8.02.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260804:nNDL7FG2Qk:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Xeris Biopharma President, COO Kevin McCulloch Sells 15,000 Shares for $120,240","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","XERS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653742392","title":"Xeris Biopharma to Report Q2 Results, Host Conference Call","url":"https://stock-news.laohu8.com/highlight/detail?id=2653742392","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653742392?lang=en_us&edition=fundamental","pubTime":"2026-07-23 19:30","pubTimestamp":1784806220,"startTime":"0","endTime":"0","summary":"Xeris Biopharma to report Q2 results, host conference callXeris Biopharma will release second-quarter 2026 financial results before the U.S. market opens on Aug. 6, 2026.Management will host a confere","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260723:nNDLb1xL4s:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","XERS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649958307","title":"Xeris Biopharma CFO Steven Pieper Disposes of 45,000 Common Shares Worth $385,876.20","url":"https://stock-news.laohu8.com/highlight/detail?id=2649958307","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649958307?lang=en_us&edition=fundamental","pubTime":"2026-07-08 05:11","pubTimestamp":1783458719,"startTime":"0","endTime":"0","summary":"Xeris Biopharma CFO Steven Pieper disposes of 45,000 common shares worth $385,876.20Xeris Biopharma CFO Steven Pieper sold 45,000 common shares in two trades on July 6-7, SEC filing shows.Sales priced","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260707:nNDL3SgY8N:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Xeris Biopharma CFO Steven Pieper Disposes of 45,000 Common Shares Worth $385,876.20","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","XERS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649649033","title":"Xeris Names John Shannon as Chair of the Board","url":"https://stock-news.laohu8.com/highlight/detail?id=2649649033","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649649033?lang=en_us&edition=fundamental","pubTime":"2026-07-06 15:21","pubTimestamp":1783322486,"startTime":"0","endTime":"0","summary":"June 30 (Reuters) - Xeris Biopharma Holdings Inc::*XERIS ANNOUNCES UPDATES TO ITS BOARD OF DIRECTORS*XERIS BIOPHARMA HOLDINGS - APPOINTS JOHN SHANNON AS CHAIR OF THE BOARD*XERIS BIOPHARMA HOLDINGS - M","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260706:nRSD848rYw:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XERS","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649974226","title":"Why Xeris Biopharma (XERS) Is Up 7.7% After Governance, IP, And Balance Sheet Moves - And What's Next","url":"https://stock-news.laohu8.com/highlight/detail?id=2649974226","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649974226?lang=en_us&edition=fundamental","pubTime":"2026-07-05 08:26","pubTimestamp":1783211218,"startTime":"0","endTime":"0","summary":"Xeris Biopharma Holdings recently combined governance and capital structure moves, including appointing CEO John Shannon as Board Chair, adding experienced biotech executive and physician Dr. Nerissa Kreher to expand the Board to eight directors, securing a USPTO notice of allowance for a Keveyis patent expected to extend protection through 2039, and retiring about US$23,000,000 of its 8.00% Convertible Senior Notes due 2028.\nTaken together, these leadership changes, intellectual property...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-xers/xeris-biopharma-holdings/news/why-xeris-biopharma-xers-is-up-77-after-governance-ip-and-ba","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-xers/xeris-biopharma-holdings/news/why-xeris-biopharma-xers-is-up-77-after-governance-ip-and-ba","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU1169590202.USD","IP","LU2463526074.USD","LU1169589451.USD","LU1481600234.SGD","XERS","BK4585","LU1487256676.USD","LU1481599808.USD","BK4136","BK4007","IE00B3T34201.USD","AIPO","BK4588","WOOD","CUT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648636191","title":"Xeris Biopharma Director Nerissa Kreher Files Initial Beneficial Ownership Statement","url":"https://stock-news.laohu8.com/highlight/detail?id=2648636191","media":"Reuters","labels":["executive","shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2648636191?lang=en_us&edition=fundamental","pubTime":"2026-07-03 06:00","pubTimestamp":1783029615,"startTime":"0","endTime":"0","summary":"Xeris Biopharma director Nerissa Kreher files initial beneficial ownership statementXeris Biopharma filed an initial Form 3 for director Nerissa Kreher, dated July 1.Disclaimer:This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Xeris Biopharma Holdings Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on July 02, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260702:nNDLg02Rk:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XERS","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648633176","title":"Xeris Biopharma Chief Legal Officer Beth Hecht Sells 16,666 Shares Worth $133,865.06","url":"https://stock-news.laohu8.com/highlight/detail?id=2648633176","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2648633176?lang=en_us&edition=fundamental","pubTime":"2026-07-03 04:40","pubTimestamp":1783024819,"startTime":"0","endTime":"0","summary":"Xeris Biopharma Chief Legal Officer Beth Hecht sells 16,666 shares worth $133,865.06Xeris Biopharma Chief Legal Officer, Corporate Secretary Beth Hecht sold 16,666 common shares on July 1.Shares were ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260702:nNDL9jxm4x:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Xeris Biopharma Chief Legal Officer Beth Hecht Sells 16,666 Shares Worth $133,865.06","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","XERS"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.xerispharma.com","stockEarnings":[{"period":"1week","weight":-0.0343},{"period":"1month","weight":0.0446},{"period":"3month","weight":0.4067},{"period":"6month","weight":0.3904},{"period":"1year","weight":0.0779},{"period":"ytd","weight":0.0752}],"compareEarnings":[{"period":"1week","weight":0.0047},{"period":"1month","weight":0.0268},{"period":"3month","weight":0.0098},{"period":"6month","weight":0.1196},{"period":"1year","weight":0.1891},{"period":"ytd","weight":0.1248}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase I clinical trial for the treatment of hypothyroidism; and non-aqueous XeriSol and XeriJect technologies for various therapies. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.","yearOnYearQuotes":[{"month":1,"riseRate":0.375,"avgChangeRate":-0.070057},{"month":2,"riseRate":0.625,"avgChangeRate":-0.03111},{"month":3,"riseRate":0.5,"avgChangeRate":-0.033138},{"month":4,"riseRate":0.5,"avgChangeRate":0.033714},{"month":5,"riseRate":0.75,"avgChangeRate":0.150943},{"month":6,"riseRate":0.5,"avgChangeRate":-0.023256},{"month":7,"riseRate":0.555556,"avgChangeRate":-0.006473},{"month":8,"riseRate":0.666667,"avgChangeRate":0.189837},{"month":9,"riseRate":0.375,"avgChangeRate":-0.064053},{"month":10,"riseRate":0.5,"avgChangeRate":-0.004147},{"month":11,"riseRate":0.5,"avgChangeRate":-0.025098},{"month":12,"riseRate":0.625,"avgChangeRate":0.051713}],"exchange":"NASDAQ","name":"Xeris Pharmaceuticals Inc","nameEN":"Xeris Pharmaceuticals Inc"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.49.0","shortVersion":"4.49.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Xeris Pharmaceuticals Inc(XERS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Xeris Pharmaceuticals Inc(XERS) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Xeris Pharmaceuticals Inc,XERS,Xeris Pharmaceuticals Inc股票,Xeris Pharmaceuticals Inc股票老虎,Xeris Pharmaceuticals Inc股票老虎国际,Xeris Pharmaceuticals Inc行情,Xeris Pharmaceuticals Inc股票行情,Xeris Pharmaceuticals Inc股价,Xeris Pharmaceuticals Inc股市,Xeris Pharmaceuticals Inc股票价格,Xeris Pharmaceuticals Inc股票交易,Xeris Pharmaceuticals Inc股票购买,Xeris Pharmaceuticals Inc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Xeris Pharmaceuticals Inc(XERS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Xeris Pharmaceuticals Inc(XERS) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}